Concord Drugs Ltd vs Gufic Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 83.95 as of 07 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 74.8 on March 2024 to 25.9 on March 2023 . This represents a CAGR of -23.29% over 4 yearsThe P/E Ratio of Gufic BioSciences Ltd changed from 33 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 years The Market Cap of Concord Drugs Ltd changed from ₹ 35.17 crore on March 2024 to ₹ 25.57 crore on March 2023 . This represents a CAGR of -7.66% over 4 yearsThe Market Cap of Gufic BioSciences Ltd changed from ₹ 2839 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 4 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Gufic BioSciences Ltd for the Dec '25 is ₹ 232.2 crore as compare to the Sep '25 revenue of ₹ 239.17 crore. This represent the decline of -2.91% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Gufic BioSciences Ltd for the Dec '25 is ₹ 33.77 crore as compare to the Sep '25 ebitda of ₹ 39.96 crore. This represent the decline of -15.49% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Gufic BioSciences Ltd changed from ₹ 20.86 crore to ₹ 12.42 crore over 7 quarters. This represents a CAGR of -25.64% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gufic BioSciences Ltd changed from 2.19 % on March 2021 to 1.43 % on March 2025 . This represents a CAGR of -8.17% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Gufic BioSciences Ltd

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
The Company was incorporated in July, 1984.
The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

FAQs for the comparison of Concord Drugs Ltd and Gufic BioSciences Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Gufic BioSciences Ltd?

Market cap of Concord Drugs Ltd is 108 Cr while Market cap of Gufic BioSciences Ltd is 2,938 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Gufic BioSciences Ltd?

The stock performance of Concord Drugs Ltd and Gufic BioSciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Gufic BioSciences Ltd?

As of May 7, 2026, the Concord Drugs Ltd stock price is INR ₹82.65. On the other hand, Gufic BioSciences Ltd stock price is INR ₹293.0.

How do dividend payouts of Concord Drugs Ltd and Gufic BioSciences Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Gufic BioSciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.